Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's Abbreviated New Drug ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News

Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market PerformOctober 4, 2017 10:44 AM Mylan (MYL) PT Raised to $45 at BTIG Following Copaxone Generic ApprovalOctober 4, 2017 7:27 AM Mylan's (MYL) Surprise Copaxone Generic Approval 'Quite Negative' for Teva Pharma (TEVA) - MizuhoOctober 4, 2017 7:02 AM Momenta Phama (MNTA) on Watch After Mylan (MYL) Granted FDA Approval of First Generic for CopaxoneOctober 4, 2017 6:42 AM Teva (TEVA) Shares Pressured After Mylan (MYL) Granted FDA Approval of First Generic for CopaxoneOctober 4, 2017 6:14 AM Mylan Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day ExclusivityOctober 3, 2017 9:58 PM